Jeremy Chadwick Sells 1,300 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 1,300 shares of Kymera Therapeutics stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $90.00, for a total transaction of $117,000.00. Following the transaction, the chief operating officer directly owned 61,202 shares in the company, valued at $5,508,180. This trade represents a 2.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Kymera Therapeutics Price Performance

Shares of KYMR stock opened at $87.71 on Friday. The firm’s 50-day moving average is $84.06 and its two-hundred day moving average is $74.43. Kymera Therapeutics, Inc. has a 12 month low of $25.50 and a 12 month high of $103.00. The company has a market capitalization of $7.16 billion, a PE ratio of -23.83 and a beta of 2.28.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). The company had revenue of $2.87 million during the quarter, compared to analysts’ expectations of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. Kymera Therapeutics’s revenue was down 60.8% on a year-over-year basis. During the same period last year, the firm posted ($0.88) earnings per share. Sell-side analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Institutional Investors Weigh In On Kymera Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Baker BROS. Advisors LP increased its stake in Kymera Therapeutics by 30.2% during the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after buying an additional 2,005,813 shares during the period. Avoro Capital Advisors LLC increased its stake in Kymera Therapeutics by 17.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after buying an additional 1,124,747 shares during the period. Vanguard Group Inc. increased its stake in Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after buying an additional 845,922 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after buying an additional 1,061,957 shares during the period. Finally, State Street Corp increased its stake in Kymera Therapeutics by 9.4% during the 4th quarter. State Street Corp now owns 2,209,837 shares of the company’s stock worth $171,947,000 after buying an additional 190,383 shares during the period.

Analyst Ratings Changes

KYMR has been the topic of a number of research analyst reports. Piper Sandler boosted their price target on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. Stephens boosted their price target on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a research note on Monday, March 2nd. UBS Group boosted their price target on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. Barclays boosted their price target on shares of Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a research note on Tuesday, January 27th. Finally, Citigroup boosted their price target on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.90.

Key Stories Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Several sell‑side analysts maintain bullish views and have raised price targets this quarter (Piper Sandler, Morgan Stanley, Stephens, BTIG), supporting demand for the shares and helping lift sentiment.
• Positive Sentiment: Small institutional increases were reported (several asset managers added modest stakes), which can provide incremental buying support in a thin float biotech. Institutional Activity
• Neutral Sentiment: Director Bruce Booth sold multiple tranches (April 14–15) totaling several thousand shares, but those sales were executed under a pre‑arranged Rule 10b5‑1 plan, which investors often view as scheduled liquidity rather than a change in insider conviction. SEC Form 4
• Negative Sentiment: COO Jeremy G. Chadwick sold a series of shares (total reported ~6,551 shares across April 14–15 at ~ $90 each) that reduced his stake; these transactions were disclosed without a 10b5‑1 designation, which can raise investor concern and likely pressured intraday trading. SEC Filing
• Negative Sentiment: Another insider, Noah Goodman, sold ~1,347 shares on April 14 (~$90/share) without a stated 10b5‑1 plan, further trimming insider ownership and adding to near‑term selling pressure. SEC Filing
• Negative Sentiment: Fundamentals remain a caution: the company missed Q4 EPS and revenue estimates in February (significant revenue shortfall year‑over‑year), which keeps the longer‑term risk profile elevated for a clinical‑stage biotech. Earnings & Key Metrics

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.